Parameter | MPACT [7, 8, 19] | Chinese Study |
|---|
n | 431 | 83 |
OS, median, months | 8.7 | 9.2 |
NLR ≤ 5 | 9.1 | 10.0 |
NLR > 5 | 5.0 | 8.3 |
PFS, median, monthsa
| 5.5 | 5.5 |
ORR, %a
| 23 | 35 |
DCR, % | 48 | 55 |
DOR, median, months | 11.1 | 8.9 |
-
DCR disease control rate, DOR duration of response, NLR neutrophil-to-lymphocyte ratio, MPACT Metastatic Pancreatic Adenocarcinoma Clinical Trial, ORR overall response rate, OS overall survival, PFS progression-free survival
-
aIndependently assessed
